If you mentioned “orphan drugs” to a pharma audience even three years ago, just a handful of drug manufacturers would likely have come to mind: the pioneer Genzyme Corp., naturally, along with comrades-in-arms Shire PLC, BioMarin Pharmaceutical Inc., and Actelion Pharmaceuticals Ltd. Well, things have changed.
In the last 18 months alone, Genzyme was acquired by Sanofi[See Deal], Pfizer Inc. launched Elelyso (taliglucerase) for the rare condition Gaucher’s disease, and GlaxoSmithKline...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?